BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

945 related articles for article (PubMed ID: 31533767)

  • 1. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status.
    Castillo D; Yuan TA; Nehoray B; Cervantes A; Tsang KK; Yang K; Sand SR; Mokhnatkin J; Herzog J; Slavin TP; Hyman S; Schwartz A; Ebert BL; Amos CI; Garber JE; Weitzel JN
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1621-1629. PubMed ID: 35654360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misdiagnosis of Li-Fraumeni Syndrome in a Patient With Clonal Hematopoiesis and a Somatic
    Mitchell RL; Kosche C; Burgess K; Wadhwa S; Buckingham L; Ghai R; Rotmensch J; Klapko O; Usha L
    J Natl Compr Canc Netw; 2018 May; 16(5):461-466. PubMed ID: 29752319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of TP53 mosaic variants found on germline genetic testing.
    Ward A; Farengo-Clark D; McKenna DB; Safonov A; Good M; Le A; Kessler L; Shah PD; Bradbury AR; Domchek SM; Nathanson KL; Powers J; Maxwell KN
    Cancer Genet; 2024 Jun; 284-285():43-47. PubMed ID: 38677009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
    Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
    Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apparently Heterozygous TP53 Pathogenic Variants May Be Blood Limited in Patients Undergoing Hereditary Cancer Panel Testing.
    Mester JL; Jackson SA; Postula K; Stettner A; Solomon S; Bissonnette J; Murphy PD; Klein RT; Hruska KS
    J Mol Diagn; 2020 Mar; 22(3):396-404. PubMed ID: 31881331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next generation sequencing is informing phenotype: a TP53 example.
    O'Shea R; Clarke R; Berkley E; Giffney C; Farrell M; O'Donovan E; Gallagher DJ
    Fam Cancer; 2018 Jan; 17(1):123-128. PubMed ID: 28509937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.
    Xavier CB; Link R; Abreu L; Bettoni F; Marson F; Galante PAF; Masotti C; Amano MT; de Molla V; Camargo AA; Asprino PF; Sabbaga J
    Oncologist; 2023 Jul; 28(7):624-627. PubMed ID: 37159554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New surveillance guidelines for Li-Fraumeni and hereditary TP53 related cancer syndrome: implications for germline TP53 testing in breast cancer.
    Evans DG; Woodward ER
    Fam Cancer; 2021 Jan; 20(1):1-7. PubMed ID: 32984917
    [No Abstract]   [Full Text] [Related]  

  • 13. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
    Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
    Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paired Tumor-Normal Sequencing Provides Insights Into the TP53-Related Cancer Spectrum in Patients With Li-Fraumeni Syndrome.
    Ceyhan-Birsoy O; Selenica P; Chui MH; Jayakumaran G; Ptashkin R; Misyura M; Aypar U; Jairam S; Yang C; Li Y; Mehta N; Kemel Y; Salo-Mullen E; Maio A; Sheehan M; Zehir A; Carlo M; Latham A; Stadler Z; Robson M; Offit K; Ladanyi M; Walsh M; Reis-Filho JS; Mandelker D
    J Natl Cancer Inst; 2021 Nov; 113(12):1751-1760. PubMed ID: 34240179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
    Bakhuizen JJ; Hogervorst FB; Velthuizen ME; Ruijs MW; van Engelen K; van Os TA; Gille JJ; Collée M; van den Ouweland AM; van Asperen CJ; Kets CM; Mensenkamp AR; Leter EM; Blok MJ; de Jong MM; Ausems MG
    Fam Cancer; 2019 Apr; 18(2):273-280. PubMed ID: 30607672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis.
    Kawai M; Iijima-Yamashita Y; Taguchi I; Kataoka M; Sanada M; Murakami Y; Kitagawa C; Hattori H
    Am J Case Rep; 2022 Jun; 23():e936455. PubMed ID: 35700150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW; Verhoef S; Rookus MA; Pruntel R; van der Hout AH; Hogervorst FB; Kluijt I; Sijmons RH; Aalfs CM; Wagner A; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gomez Garcia EB; Meijers-Heijboer H; Ten Kate LP; Menko FH; van 't Veer LJ
    J Med Genet; 2010 Jun; 47(6):421-8. PubMed ID: 20522432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline TP53 pathogenic variants and breast cancer: A narrative review.
    Blondeaux E; Arecco L; Punie K; Graffeo R; Toss A; De Angelis C; Trevisan L; Buzzatti G; Linn SC; Dubsky P; Cruellas M; Partridge AH; Balmaña J; Paluch-Shimon S; Lambertini M
    Cancer Treat Rev; 2023 Mar; 114():102522. PubMed ID: 36739824
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 48.